A phase I dose-escalation study of CST-101 in patients with Advanced Renal Cell Carcinoma and Melanoma susceptible to immunotherapies.
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2016
At a glance
- Drugs CST 101 (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions
- 17 Mar 2016 New trial record
- 07 Feb 2016 Clinical data from the first 12 patients of the U.S. trial at Rush University Medical Center in Chicago has been announced recently, as per the University of Pittsburgh Medical Center (UPMC) media release.